Capital Investment Advisors LLC Has $11.79 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Capital Investment Advisors LLC trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 70.3% in the third quarter, according to its most recent filing with the SEC. The firm owned 106,239 shares of the biopharmaceutical company’s stock after selling 251,900 shares during the period. Capital Investment Advisors LLC’s holdings in Gilead Sciences were worth $11,792,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Brighton Jones LLC boosted its holdings in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 2,450 shares in the last quarter. Bison Wealth LLC bought a new position in shares of Gilead Sciences during the 4th quarter worth approximately $215,000. Caxton Associates LLP acquired a new stake in Gilead Sciences in the 1st quarter valued at $562,000. SCS Capital Management LLC acquired a new stake in Gilead Sciences in the 1st quarter valued at $853,000. Finally, Advisory Alpha LLC grew its position in Gilead Sciences by 25.6% in the first quarter. Advisory Alpha LLC now owns 3,536 shares of the biopharmaceutical company’s stock valued at $396,000 after acquiring an additional 721 shares during the period. Institutional investors own 83.67% of the company’s stock.

Insider Activity

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $125.08, for a total value of $625,400.00. Following the transaction, the director owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. This represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $122.00, for a total value of $366,000.00. Following the transaction, the insider owned 106,221 shares of the company’s stock, valued at $12,958,962. The trade was a 2.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 136,257 shares of company stock worth $16,855,192. Corporate insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on GILD. Morgan Stanley lifted their price objective on Gilead Sciences from $147.00 to $151.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Scotiabank started coverage on shares of Gilead Sciences in a report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price target for the company. Argus upped their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Wells Fargo & Company raised their price objective on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, December 10th. Finally, Mizuho lifted their target price on shares of Gilead Sciences from $131.00 to $140.00 and gave the company an “outperform” rating in a research note on Friday, November 21st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $133.20.

Gilead Sciences Trading Down 3.0%

Shares of NASDAQ GILD opened at $120.67 on Friday. Gilead Sciences, Inc. has a 1-year low of $88.57 and a 1-year high of $128.70. The company has a market cap of $149.71 billion, a PE ratio of 18.71, a P/E/G ratio of 0.66 and a beta of 0.33. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The company has a 50-day moving average of $123.24 and a two-hundred day moving average of $117.41.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. Gilead Sciences’s revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend was Monday, December 15th. Gilead Sciences’s payout ratio is currently 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.